Risk of secondary cancers after CAR T therapy may be similar to risk after other cancer treatments

Estimated reading time: 1 minutes

• About The Author

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other standard-of-care therapies, according to a systematic review and meta-analysis.

About The Author

See author's posts

Trending

Android malware steals payment card data using previously unseen technique